Table 1.

The Difference of Basic Characteristics in Responders and Non-Responders

Characteristics	Responders	Non-Responders	p-value
	n (%)	n (%)
Age (range), years	60 (31–83)	60 (33–80)	0.778
≥60	80 (53.3%)	34 (51.5%)
˂60	70 (46.7%)	32 (48.5%)
Gender			0.517
Male	64 (42.7%)	27 (40.9%)
Female	86 (57.3%)	39 (59.1%)
Smoking history			0.558
Current smoker	24 (16.0%)	13 (19.7%)
Non-smoker	126 (84.0%)	53 (80.3%)
ECOG PS
0	80 (53.3%)	22 (33.3%)	0.006
1	66 (44.0%)	44 (66.7%)
2	4 (2.7%)	0
EGFR mutation			0.790
Common
Exon 19 deletion	79 (52.7%)	33 (50.0%)
Exon 21 L858R	67 (44.7%)	32 (48.5%)
Uncommon
Exon 18 G719	4 (2.6%)	1 (1.5%)
Liver metastasis			0.001
Presence	7 (4.7%)	12 (18.2%)
Absence	143 (95.3%)	54 (81.8%)
Adrenal metastasis			0.561
Presence	6 (4.0%)	4 (6.1%)
Absence	144 (96.0%)	62 (93.9%)
Peritoneal metastasis			0.549
Presence	1 (0.7%)	1 (1.5%)
Absence	149 (99.3%)	65 (98.5%)
Leptomeningeal Metastases			0.808
Presence	3 (2.0%)	1 (1.5%)
Absence	147 (98.0%)	65 (98.5%)
Brain parenchyma metastasis			0.993
Presence	41 (27.3%)	18 (27.3%)
Absence	109 (72.7%)	48 (72.7%)
Pericardial metastasis			0.678
Presence	6 (4.0%)	1 (1.5%)
Absence	144 (96.0%)	65 (98.5%)
Extrathoracic lymph node metastasis			0.001
Presence	26 (17.3%)	26 (39.4%)
Absence	124 (82.7%)	40 (60.6%)
Lung metastasis (contralateral)
Presence	61 (40.7%)	30 (45.5%)	0.551
Absence	89 (59.3%)	36 (54.5%)
Pleural metastasis			0.754
Presence	48 (32.0%)	23 (34.8%)
Absence	102 (68.0%)	43 (65.2%)
Bone metastasis			0.235
Presence	63 (42.0%)	34 (51.5%)
Absence	87 (58.0%)	32 (48.5%)
Metastasis to other organs			0.678
Presence	6 (4.0%)	1 (1.5%)
Absence	144 (96.0%)	65 (98.5%)
Number of organs with metastasis			0.037
Single-organ	74 (49.3%)	22 (33.3%)
Multi-organ	76 (50.7%)	44 (66.7%)
Total patients	150	66

Notes: Responders: patients with CR/PR to icotinib; non-responders: patients with SD/PD to icotinib.

Abbreviation: ECOG PS, Eastern Cooperative Oncology Group Performance Status at diagnosis.